Vnitr Lek 2016, 62(4):281-286

Prothrombin gene 20210A mutation in Slovak population

Juraj Chudej*, Ivana Plameňová
Department of Haematology and Transfusion Medicine, National Centre for Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia

Introduction:
Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). PTM is present in 2 % Caucasian population. The main aim of this study was to identify the PTM in the patients with positive history of thrombotic events vs. control subjects.

Materials and Methods:
The assessment of PTM was performed by the PCR analysis of the chromosomal DNA, which was isolated from the peripheral blood leukocytes.

Results:
Of the 2 274 patients included, 157 (6.9 %) were carriers of the PTM. The mutation was present only in 2.6 % (n = 8) of the 303 controls. The following clinical manifestations of PTM were analysed. We observed 123 venous thrombotic events, 46 arterial thrombosis and 14 spontaneous abortions. In this article we analyse other possible risk factors for thromboembolic events in patients with carriage of PTM.

Conclusions:
To our knowledge, this is the largest epidemiological study of PTM in Central Europe. Employing statistical analysis, we found relatively high prevalence of the PTM in both, the patients with positive thrombosis history (6.9 %), as well as in the control group (2.6 %). The risk of thrombosis by carriage of PTM is independent of age and gender. Study has shown relatively frequent presence of double carriership of PTM and factor V Leiden mutation (FVL).

Keywords: mutation; population; prothrombin; thrombophilia; thrombosis

Received: July 9, 2015; Accepted: February 1, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chudej J, Plameňová I. Prothrombin gene 20210A mutation in Slovak population. Vnitr Lek. 2016;62(4):281-286.
Download citation

References

  1. Chang MH, Lindegren ML, Butler MA et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol 2009; 169(1): 54-66. Go to original source... Go to PubMed...
  2. Degen SJ, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1987; 26(19): 6165-6177. Go to original source... Go to PubMed...
  3. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88(10): 3698-3703. Go to original source...
  4. Simioni P, Tormene D, Manfrin D et al. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103(4): 1045-1050. Go to original source... Go to PubMed...
  5. Kyrle PA, Mannhalter C, Beguin S et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18(8):1287-1291. Go to original source... Go to PubMed...
  6. Zawadzki C, Gaveriaux V, Trillot N et al. Homozygous G20210A transition in the prothrombin gene associated with severe venous thrombotic disease: two cases in a French family. Thromb Haemost 1998; 80(6): 1027-1028. Go to original source... Go to PubMed...
  7. Morange PE, Barthet MC, Henry M et al. A three-generation family presenting five cases of homozygosity for the 20210 G to A prothrombin variant. Thromb Haemost 1998; 80(5): 859-860. Go to original source... Go to PubMed...
  8. Eikelboom JW, Ivey L, Ivey J et al. Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. Blood Coagul Fibrinolysis 1999; 10(1): 1-5. Go to original source...
  9. Corral J, Zuazu-Jausoro I, Rivera J et al. Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large family. Br J Haematol 1999; 105(2): 560-563. Go to original source... Go to PubMed...
  10. Zivelin A, Rosenberg N, Faier S et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 1998; 92(4): 1119-1124. Go to original source...
  11. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99(8): 999-1004. Go to original source... Go to PubMed...
  12. Kapur RK, Mills LA, Spitzer SG et al. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol 1997; 17(11): 2875-2879. Go to original source... Go to PubMed...
  13. Margaglione M, Brancaccio V, Giuliani N et al. Increased risk for venous thrombosis in carriers of the prothrombin G->A20210 gene variant. Ann Intern Med 1998; 129(2): 89-93. Go to original source... Go to PubMed...
  14. Alhenc-Gelas M, Arnaud E, Nicaud V et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81(4): 506-510. Go to original source... Go to PubMed...
  15. Nowak-Gottl U, Junker R, Kreuz W et al. (Childhood Thrombophilia Study Group). Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97(4): 858-862. Go to original source... Go to PubMed...
  16. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS et al. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78(6): 1430-1433. Go to original source... Go to PubMed...
  17. Gurgey A, Kudayarov DK, Tuncer M et al. The factor V Leiden and prothrombin G20210A mutations in Kirghiz population. Thromb Haemost 2000; 84(2): 356. Go to original source... Go to PubMed...
  18. Dilley A, Austin H, Hooper WC et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998; 132(6): 452-455. Go to original source... Go to PubMed...
  19. Ho CH. Prevalence of prothrombin 20210A allele and methylenetetrahydrofolate reductase C677T genetic mutations in the Chinese population. Ann Hematol 2000; 79(5): 239-242. Go to original source... Go to PubMed...
  20. Vandenbroucke JP, Rosing J, Bloemenkamp KW et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344(20): 1527-1535. Go to original source...
  21. Martinelli I, Taioli E, Bucciarelli P et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19(3): 700-703. Go to original source... Go to PubMed...
  22. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342(6): 374-380. Go to original source... Go to PubMed...
  23. Sokol J, Biringer K, Skerenova M et al. Platelet aggregation abnormalities in patients with fetal losses: the GP6 gene polymorphism. Fertil Steril 2012; 98(5): 1170-1174. Go to original source... Go to PubMed...
  24. Sokol J, Biringer K, Skerenova M et al. Different models of inheritance in selected genes in patients with sticky platelet syndrome and fetal loss. Semin Thromb Hemost 2015; 41(3): 330-335. Go to original source... Go to PubMed...
  25. Sokol J, Biringer K, Skerenova M et al. Activity of coagulation factor XI in patients with spontaneous miscarriage: The presence of risk alleles. J Obstet Gynaecol 2015; 35(6): 621-624. Go to original source... Go to PubMed...
  26. Šimonová R, Bartosová L, Chudy P et al. Nine kindreds of familial sticky platelet syndrome phenotype. Clin Appl Thromb Hemost 2013; 19(4): 395-401. Go to original source... Go to PubMed...
  27. Francs F, Portols O, Gabriel F et al. Factor V Leiden (G1691A) and prothrombin-G20210A alleles among patients with deep venous thrombosis and in the general population from Spain. Rev Med Chil 2006; 134(1): 13-20. Go to PubMed...
  28. Alvarez A, Barroso A, Robledo M et al. Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes. Sangre (Barc) 1999; 44(1): 7-12. Go to PubMed...
  29. Souto JC, Coll I, Llobet D et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80(3): 366-369. Go to original source... Go to PubMed...
  30. Leroyer C, Mercier B, Oger E et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80(1): 49-51. Go to original source... Go to PubMed...
  31. Mazoyer E, Ripoll L, Gueguen R et al. (FITENAT Study Group). Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagul Fibrinolysis 2009; 20(7): 503-510. Go to original source... Go to PubMed...
  32. Reny JL, Alhenc-Gelas M, Fontana P et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. J Thromb Haemost 2004; 2(8): 1334-1340. Go to original source... Go to PubMed...
  33. Martinelli I, Bucciarelli P, Margaglione M et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111(4): 1223-1239. Go to original source... Go to PubMed...
  34. de Moerloose P, Reber G, Perrier A et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110(1): 125-129. Go to original source... Go to PubMed...
  35. Sottilotta G, Mamm C, Furl G et al. High incidence of factor V Leiden and prothrombin G20210A in healthy southern Italians. Clin Appl Thromb Hemost 2009; 15(3): 356-359. Go to original source... Go to PubMed...
  36. Tosetto A, Missiaglia E, Frezzato M et al. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999; 82(5): 1395-1398. Go to original source... Go to PubMed...
  37. Bedencic M, Bozic M, Peternel P et al. Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia. Pathophysiol Haemost Thromb 2008; 36(2): 58-63. Go to original source... Go to PubMed...
  38. Zerjavic K, Zagradisnik B, Stangler Herodez S et al. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis? Acta Haematol 2010; 124(1): 49-56. Go to original source... Go to PubMed...
  39. Jukic I, Bingulac-Popovic J, Dogic V et al. ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croat Med J 2009; 50(6): 550-558. Go to original source... Go to PubMed...
  40. Herak DC, Antolic MR, Krleza JL et al. Inherited prothrombotic risk factors in children with stroke, transient ischemic attack, or migraine. Pediatrics 2009; 123(4): e653-e660. Dostupné z DOI: <http://dx.doi.org/10.1542/peds.2007-3737>. Go to original source... Go to PubMed...
  41. Eterović D, Titlić M, Culić V et al. Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors: pair-matched case-control study. Clin Appl Thromb Hemost 2007; 13(2): 188-193. Go to original source... Go to PubMed...
  42. Coen D, Zadro R, Honović L et al. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J 2001; 42(4): 488-492. Go to PubMed...
  43. Djordjevic V, Rakicevic LJ, Mikovic D et al. Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol 2004; 112(4): 227-229. Go to original source... Go to PubMed...
  44. Foka ZJ, Lambropoulos AF, Makris PE et al. High frequency of factor V Leiden and prothrombin G20210A mutations in Greek hemophiliacs. J Thromb Haemost 2003; 1(5): 1116-1167. Go to original source... Go to PubMed...
  45. Hatzaki A, Anagnostopoulou E, Metaxa-Mariatou V et al. The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients. Int Angiol 2003; 22(1): 79-82. Go to PubMed...
  46. Zalavras CG, Giotopoulou S, Dokou E et al. Prevalence of the G20210A prothrombin gene mutation in Northwestern Greece and association with venous thromboembolism. Int Angiol 2003; 22(1): 55-57. Go to PubMed...
  47. Antoniadi T, Hatzis T, Kroupis C et al. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999; 61(4): 265-267. Go to original source... Go to PubMed...
  48. Tug E, Aydin H, Kaplan E et al. Frequency of genetic mutations associated with thromboembolism in the Western Black Sea Region. Intern Med 2011; 50(1): 17-21. Go to original source... Go to PubMed...
  49. Altinisik J, Ates O, Ulutin T et al. Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients. Clin Appl Thromb Hemost 2008; 14(4): 415-420. Go to original source... Go to PubMed...
  50. Irdem A, Devecioglu C, Batun S et al. Prevalence of factor V Leiden and prothrombin G20210A gene mutation. Saudi Med J 2005; 26(4): 580-583. Go to PubMed...
  51. Xenophontos SL, Hadjivassiliou M, Ayrton N et al. Spectrum and prevalence of prothrombotic single nucleotide polymorphism profiles in the Greek Cypriot population. Int Angiol 2002; 21(4): 322-329. Go to PubMed...
  52. Angelopoulou K, Nicolaides A, Constantinou DC. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost 2000; 6(2): 104-107. Go to original source... Go to PubMed...
  53. Barcellona D, Fenu L, Cauli C et al. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost. 2003; 90(6): 1061-1064. Go to original source... Go to PubMed...
  54. Hillarp A, Zoller B, Svensson PJ et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78(3): 990-992. Go to original source... Go to PubMed...
  55. Kvasnička J. Doporučený postup pro indikaci molekulárně genetických vyšetření v rámci diagnostiky trombofilních stavů v žilním systému. Vnitř Lék 2010; 56(12): 1251. Go to PubMed...
  56. Dulíček P. Trombofilní stavy. Vnitř Lék 2005; 91(7-8): 819-825.
  57. Piťha J, Auzký O, Roztočil K. Co mají společného žilní a tepenná onemocnéní? Vnitř Lék 2014; 60(11): 985-989. Go to PubMed...
  58. Dulíček P, Vodičková L, Malý J et al., ,Nejasná" príčina vzniku recidívy venózneho tromboembolizmu. Vnitř Lék 2006; 52(1): 87-88. Go to PubMed...
  59. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Int Med 2001; 135(5): 367-373. Go to original source... Go to PubMed...
  60. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114(3): 512-528. Go to original source... Go to PubMed...
  61. Rosendaal FR. Venous thrombosis: multicausal disease. Lancet 1999; 353(9159): 1167-1173. Go to original source... Go to PubMed...
  62. Dahl OE. Mechanisms of hypercoagulability. Thromb Haemost 1999; 82(2): 902-906. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.